[HTML][HTML] Transmission of 2019-nCoV infection from an asymptomatic contact in Germany
C Rothe, M Schunk, P Sothmann… - New England journal …, 2020 - Mass Medical Soc
2019-nCoV Transmission from Asymptomatic Patient In this report, investigators in Germany
detected the spread of the novel coronavirus (2019-nCoV) from a person who had recently …
detected the spread of the novel coronavirus (2019-nCoV) from a person who had recently …
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded …
…, O Schönborn-Kellenberger, M Schunk… - The Lancet Infectious …, 2022 - thelancet.com
Background Additional safe and efficacious vaccines are needed to control the COVID-19
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
Severe dengue virus infection in travelers: risk factors and laboratory indicators
O Wichmann, J Gascon, M Schunk… - The Journal of …, 2007 - academic.oup.com
Background. Dengue fever is the most common arboviral disease in travelers. In countries
where dengue virus is endemic, sequential (secondary) infections with different dengue virus …
where dengue virus is endemic, sequential (secondary) infections with different dengue virus …
[HTML][HTML] Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial
…, C Schindler, JJ Gabor, M Schunk… - Wiener Klinische …, 2021 - Springer
Background We used the RNActive® technology platform (CureVac NV, Tübingen, Germany)
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers
…, G Leroux-Roels, C Schindler, M Schunk… - MedRxiv, 2020 - medrxiv.org
There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
[HTML][HTML] Schistosomiasis in European travelers and migrants: analysis of 14 years TropNet surveillance data
…, S Marocco, B Trevino, M Schunk… - The American journal …, 2017 - ncbi.nlm.nih.gov
Schistosomiasis remains one of the most prevalent parasitic diseases worldwide and the
infection is frequently found in travelers and migrants. The European Network for Tropical …
infection is frequently found in travelers and migrants. The European Network for Tropical …
[HTML][HTML] Skin and soft tissue infections in intercontinental travellers and the import of multi-resistant Staphylococcus aureus to Europe
…, A Neumayr, A Mueller, A Kantele, M Schunk… - Clinical microbiology …, 2015 - Elsevier
Staphylococcus aureus is emerging globally. Treatment of infections is complicated by
increasing antibiotic resistance. We collected clinical data and swabs of returnees with skin and …
increasing antibiotic resistance. We collected clinical data and swabs of returnees with skin and …
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)
…, L Maboko, F Sawe, MS Schunk… - The Journal of …, 2010 - academic.oup.com
Background. Human immunodeficiency virus (HIV) vaccine development remains a global
priority. We describe the safety and immunogenicity of a multiclade DNA vaccine prime with a …
priority. We describe the safety and immunogenicity of a multiclade DNA vaccine prime with a …
[HTML][HTML] Prospective European-wide multicentre study on a blood based real-time PCR for the diagnosis of acute schistosomiasis
…, M Jensenius, P Parola, J Richter, M Schunk… - BMC infectious …, 2013 - Springer
Background Acute schistosomiasis constitutes a rare but serious condition in individuals
experiencing their first prepatent Schistosoma infection. To circumvent costly and time-…
experiencing their first prepatent Schistosoma infection. To circumvent costly and time-…
[HTML][HTML] Travel-related infections presenting in Europe: a 20-year analysis of EuroTravNet surveillance data
…, L Weld, A Goorhuis, DH Hamer, M Schunk… - The Lancet Regional …, 2021 - thelancet.com
Background Disease epidemiology of (re-)emerging infectious diseases is changing rapidly,
rendering surveillance of travel-associated illness important. Methods We evaluated travel-…
rendering surveillance of travel-associated illness important. Methods We evaluated travel-…